NCT06704152 - BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

March 31, 2029

Conditions

AML, Adult RecurrentALL, Recurrent, AdultMDS

Interventions

DRUG

SOC + BSB-1001 Dose Escalation Cohort

Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).

DRUG

SOC+BSB-1001 Expansion Dose

Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).

Trial Locations (6)

33612

RECRUITING

Moffitt Cancer Center, Tampa

43210

RECRUITING

The Ohio State University, Columbus

48109

RECRUITING

University of Michigan, Ann Arbor

55455

RECRUITING

University of Minnesota, Minneapolis

63110

RECRUITING

Washington University at St Louis, St Louis

91010

RECRUITING

City of Hope National Medical Center, Duarte